SCHEMBL1721022

SCHEMBL1721022

CCc1[nH]c(=O)c2ccccc2c1CN1CCC(O)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
POLB P06746 1/20 0.45
HPGD P15428 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PIM1 P11309 5/20 0.41
PIM2 Q9P1W9 5/20 0.41
PIM3 Q86V86 3/20 0.41
TSHR P16473 1/20 0.40
CDC7 O00311 4/20 0.39
CSNK2A2 P19784 2/20 0.39
CSNK2B P67870 2/20 0.39
CSNK2A1 P68400 2/20 0.39
CYP1A2 P05177 1/20 0.39
PARP1 P09874 2/20 0.39
BCHE P06276 1/20 0.39
LTA4H P09960 4/20 0.38
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1720911 1.00 ALDH1A1 (0.45) ALDH1A1KDM4EPOLBHPGDSMN1; SMN2
SCHEMBL1721019 1.00 ALDH1A1 (0.45) ALDH1A1KDM4EPOLBHPGDSMN1; SMN2
SCHEMBL1719858 0.93 MAPT (0.42) ALDH1A1KDM4EPARP1BCHE
SCHEMBL1719785 0.85 CDC7 (0.51) ALDH1A1KDM4EPOLBHPGDSMN1; SMN2
SCHEMBL1719992 0.85 CDC7 (0.51) ALDH1A1KDM4EPOLBHPGDSMN1; SMN2
SCHEMBL1720056 0.85 CYP19A1 (0.42) ALDH1A1KDM4EPOLBHPGDSMN1; SMN2
SCHEMBL1720570 0.85 CYP19A1 (0.42) ALDH1A1KDM4EPOLBHPGDSMN1; SMN2
SCHEMBL1720059 0.85 CYP19A1 (0.42) ALDH1A1KDM4EPOLBHPGDSMN1; SMN2
SCHEMBL1719784 0.85 CDC7 (0.51) ALDH1A1KDM4EPOLBHPGDSMN1; SMN2
SCHEMBL1719911 0.85 ALDH1A1 (0.47) ALDH1A1KDM4EPOLBHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 ALDH1A1 169/4885KDM4E 3585/4885POLB 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.